7 Jan 2026 STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy
3 Dec 2025 STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
11 Dec 2023 STRM.BIO Presents a Novel Bone Marrow/Hematopoietic Stem Cell-Targeted Extracellular Vesicle Delivery Platform for In Vivo Gene Therapy at ASH 2023
11 Oct 2023 STRM.BIO Presents Preclinical Data on a Novel Bone Marrow/HSC-Targeted, Megakaryocyte-Derived Extracellular Delivery Platform for In Vivo Gene Therapy at the Cell & Gene Meeting on the Mesa
26 Jul 2022 STRM.BIO Receives $2.1 Million SBIR Grant to Advance Extracellular Vesicle Technology for Non-Viral, In Vivo Delivery of Gene Therapies
